Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

NCT03825380 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 485

Last updated 2023-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

Conditions

Interventions

DRUG

Bimatoprost

Eyedrops

DRUG

Lumigan®

Eyedrops

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-23
Primary Completion
2021-02-03
Completion
2021-02-24

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03825380 on ClinicalTrials.gov